Inflectra to be first 'substitutable' biosimilar in Australia
This article was originally published in SRA
Australia's Pharmaceutical Benefits Advisory Committee has recommended that Hospira's biosimilar Inflectra (infliximab) - which has only just been approved as the country's first biosimilar monoclonal antibody - should be listed on the Pharmaceutical Benefits Scheme1,2. And in a highly controversial move, the PBAC has also said that Inflectra should be 'a'-flagged, meaning that it can be substituted by pharmacists for the originator drug, Johnson & Johnson's Remicade.
Register for our free email digests: